Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
letter
. 2020 Jun 22;80:26. doi: 10.1016/j.ijsu.2020.06.029

Convalescent plasma therapy in the treatment of COVID-19: Some considerations: Correspondence

Viroj Wiwanitkit 1
PMCID: PMC7307978  PMID: 32585194

Dear Editor, I would like to share ideas on “Convalescent plasma therapy in the treatment of COVID-19: practical considerations: Correspondence.” is very interesting [1]. Islam et al. noted that “While we await trial results, we recommend that CPT be considered for patients severely ill with COVID-19 upon hospitalization [1].” Convalescent plasma therapy is still not scientifically proven for its usefulness and safety. In fact, Islam et al. already mentioned for considerations on possible problem due to pathogen contamination in convalescent plasma [1]. At present, there is still no scientific proof that the presently use plasma preparation technique in all blood banks can successfully remove all pathogens. There are many other classic therapeutic options that might pose lower risk for management of COVID-19 such as the use of classic drug, hydroxychloroquine. Finally, whether the convalescent plasma can act against the novel coronavirus or not still requires further studies. There are some evidences on possible repeated COVID-19 infection in patients recovered from COVID-19 [2,3]. This can imply that there is a chance that there will be no protective immunity in plasma of patients recovered from a COVID-19 illness.

Sources of funding

None.

Ethical approval

Not applicable.

Unique identifying number (UIN)

  • 1.

    Name of the registry: not applicable

  • 2.

    Unique Identifying number or registration ID: not applicable

  • 3.

    Hyperlink to your specific registration (must be publicly accessible and will be checked):

Author contribution

Wiwanitkit 100%.

Guarantor

Professor Viroj Wiwanitkit.

Provenance and peer review

Not Commissioned, internally reviewed.

Data statement

Not applicable.

Declaration of competing interest

None.

References

  • 1.Islam A., Rafiq S., Karim S., Laher I., Rashid H. Convalescent plasma therapy in the treatment of COVID-19: practical considerations: Correspondence. Int. J. Surg. 2020 Jun 2;S1743–9191(20):30462–30463. doi: 10.1016/j.ijsu.2020.05.079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Hoang V.T., Dao T.L., Gautret P. Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19. J. Med. Virol. 2020 May 25 doi: 10.1002/jmv.26056. Online ahead of print. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Bongiovanni M., Basile F. Re-infection by COVID-19: a real threat for the future management of pandemia? Inf. Disp. 2020 May 21:1–2. doi: 10.1080/23744235.2020.1769177. [DOI] [PubMed] [Google Scholar]

Articles from International Journal of Surgery (London, England) are provided here courtesy of Elsevier

RESOURCES